Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 4/20 | 0.33 |
| ▸ | LIPE | Q05469 | 1/20 | 0.33 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.30 |
| ▸ | BTK | Q06187 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14800589 | 0.84 | CCR1 (0.32) | UCHL1 | |
| SCHEMBL15817447 | 0.83 | EGFR (0.37) | EGFRLIPE | |
| SCHEMBL30236983 | 0.79 | PDGFRB (0.31) | — | |
| SCHEMBL22657170 | 0.79 | FFAR1 (0.32) | UCHL1 | |
| SCHEMBL31378591 | 0.79 | LPL (0.39) | EGFRJAK2BTK | |
| SCHEMBL16094541 | 0.79 | PDGFRB (0.31) | — | |
| SCHEMBL17752336 | 0.79 | LPL (0.39) | EGFRJAK2BTK | |
| SCHEMBL30006214 | 0.79 | EGFR (0.38) | EGFRLIPEUCHL1 | |
| SCHEMBL16420204 | 0.79 | CRHR1 (0.32) | EGFRLIPEUCHL1 | |
| SCHEMBL14038064 | 0.79 | EGFR (0.38) | EGFRLIPEUCHL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250195480-A1 | MACROCYCLIC AZOLOPYRIDINE DERIVATIVES AS EED AND PRC2 MODULATORS | Fulcrum Therapeutics, Inc. | 2025-06-19 | — | — | US | disclosed |
| US-12109198-B2 | Macrocyclic azolopyridine derivatives as EED and PRC2 modulators | Fulcrum Therapeutics, Inc. (US) | 2024-10-08 | — | — | US | disclosed |
| US-20240139163-A1 | MACROCYCLIC AZOLOPYRIDINE DERIVATIVES AS EED AND PRC2 MODULATORS | Fulcrum Therapeutics, Inc. | 2024-05-02 | — | — | US | disclosed |
| CN-114144230-B | Macrocyclic azolopyridine derivatives as EED and PRC2 modulators | 弗尔康医疗公司 | 2024-04-23 | — | — | CN | disclosed |
| US-11590111-B2 | Macrocyclic azolopyridine derivatives as EED and PRC2 modulators | Fulcrum Therapeutics, Inc. (US) | 2023-02-28 | — | — | US | disclosed |
| US-20220160686-A1 | MACROCYCLIC AZOLOPYRIDINE DERIVATIVES AS EED AND PRC2 MODULATORS | Fulcrum Therapeutics, Inc. | 2022-05-26 | — | — | US | disclosed |
| US-20220160686-A1 | MACROCYCLIC AZOLOPYRIDINE DERIVATIVES AS EED AND PRC2 MODULATORS | Fulcrum Therapeutics, Inc. | 2022-05-26 | — | — | US | disclosed |
| CN-114144230-A | Macrocyclic azolopyridine derivatives as EED and PRC2 modulators | 弗尔康医疗公司 | 2022-03-04 | — | — | CN | disclosed |
| EP-3938050-A1 | MACROCYCLIC AZOLOPYRIDINE DERIVATIVES AS EED AND PRC2 MODULATORS | Fulcrum Therapeutics, Inc. (US) | 2022-01-19 | — | — | EP | disclosed |
| US-10973805-B2 | Macrocyclic azolopyridine derivatives as EED and PRC2 modulators | Fulcrum Therapeutics, Inc. (US) | 2021-04-13 | — | — | US | disclosed |
| US-20150368247-A1 | 2,6,7 SUBSTITUTED PURINES AS HDM2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-12-24 | — | — | US | disclosed |
| EP-2953470-A1 | 2,6,7 SUBSTITUTED PURINES AS HDM2 INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2015-12-16 | — | — | EP | disclosed |
| US-20150353553-A1 | 2,6,7,8 SUBSTITUTED PURINES AS HDM2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-12-10 | — | — | US | disclosed |
| US-20150353553-A1 | 2,6,7,8 SUBSTITUTED PURINES AS HDM2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-12-10 | — | — | US | disclosed |
| US-20150353553-A1 | 2,6,7,8 SUBSTITUTED PURINES AS HDM2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-12-10 | — | — | US | disclosed |
| EP-2951180-A1 | 2,6,7,8 SUBSTITUTED PURINES AS HDM2 INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2015-12-09 | — | — | EP | disclosed |
| WO-2014123882-A1 | 2,6,7 SUBSTITUTED PURINES AS HDM2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-08-14 | — | — | WO | disclosed |
| WO-2014123882-A1 | 2,6,7 SUBSTITUTED PURINES AS HDM2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-08-14 | — | — | WO | disclosed |
| WO-2014120748-A1 | 2,6,7,8 SUBSTITUTED PURINES AS HDM2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-08-07 | — | — | WO | disclosed |
| WO-2014120748-A1 | 2,6,7,8 SUBSTITUTED PURINES AS HDM2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150368247-A1 | 2,6,7 SUBSTITUTED PURINES AS HDM2 INHIBITORS | DDX21, NSUN2, DHX29 | EGFR 3634/4885LIPE 4816/4885UCHL1 3077/4885 |
| US-10973805-B2 | Macrocyclic azolopyridine derivatives as EED and PRC2 modulators | EED, EZH2, BMI1 | EGFR 1842/4885LIPE 4848/4885UCHL1 3173/4885 |
| US-12109198-B2 | Macrocyclic azolopyridine derivatives as EED and PRC2 modulators | EED, EZH2, BMI1 | EGFR 1842/4885LIPE 4848/4885UCHL1 3173/4885 |
| US-20250195480-A1 | MACROCYCLIC AZOLOPYRIDINE DERIVATIVES AS EED AND PRC2 MODULATORS | EED, EZH2, BMI1 | EGFR 1842/4885LIPE 4848/4885UCHL1 3173/4885 |
| US-20220160686-A1 | MACROCYCLIC AZOLOPYRIDINE DERIVATIVES AS EED AND PRC2 MODULATORS | EED, EZH2, BMI1 | EGFR 1842/4885LIPE 4848/4885UCHL1 3173/4885 |
| US-20150353553-A1 | 2,6,7,8 SUBSTITUTED PURINES AS HDM2 INHIBITORS | DDX21, DPYD, NSUN2 | EGFR 3638/4885LIPE 4799/4885UCHL1 2924/4885 |
| US-11590111-B2 | Macrocyclic azolopyridine derivatives as EED and PRC2 modulators | EED, EZH2, BMI1 | EGFR 1842/4885LIPE 4848/4885UCHL1 3173/4885 |
| US-20240139163-A1 | MACROCYCLIC AZOLOPYRIDINE DERIVATIVES AS EED AND PRC2 MODULATORS | EED, EZH2, BMI1 | EGFR 1842/4885LIPE 4848/4885UCHL1 3173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.